

World Journal of *Clinical Cases*

World J Clin Cases 2023 April 16; 11(11): 2363-2581



Contents

Thrice Monthly Volume 11 Number 11 April 16, 2023

REVIEW

- 2363 Presbyphagia: Dysphagia in the elderly
Feng HY, Zhang PP, Wang XW

MINIREVIEWS

- 2374 Narrative minireview of the spatial epidemiology of substance use disorder in the United States: Who is at risk and where?
Cuadros DF, Branscum AJ, Moreno CM, MacKinnon NJ
- 2386 Pyroptosis and its role in cancer
Liu SW, Song WJ, Ma GK, Wang H, Yang L
- 2396 Platelet rich fibrin is not a barrier membrane! Or is it?
Agrawal AA
- 2405 Advances in translational therapy for locally advanced gastric cancer
Zhao K, Na Y, Xu HM

ORIGINAL ARTICLE

Retrospective Study

- 2412 Study of pathogenic genes in a pedigree with familial dilated cardiomyopathy
Zhang XR, Ren H, Yao F, Liu Y, Song CL
- 2423 Classification of hepatobiliary scintigraphy patterns in segmented gallbladder according to anatomical discordance
Lee YC, Jung WS, Lee CH, Kim SH, Lee SO
- 2435 Optimal laboratory testing protocol for patients with acne taking oral isotretinoin
Park YJ, Shin HY, Choi WK, Lee AY, Lee SH, Hong JS

Observational Study

- 2443 Etiology analysis for term newborns with severe hyperbilirubinemia in eastern Guangdong of China
Xu JX, Lin F, Wu YH, Chen ZK, Ma YB, Yang LY

CASE REPORT

- 2452 Aicardi-Goutières syndrome type 7 in a Chinese child: A case report
Lin SZ, Yang JJ, Xie TL, Li JY, Ma JQ, Wu S, Wang N, Wang YJ

- 2457** Allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia and pulmonary eosinophilia: A case report
Zhang XX, Zhou R, Liu C, Yang J, Pan ZH, Wu CC, Li QY
- 2464** Late presentation of dural tears: Two case reports and review of literature
Xu C, Dong RP, Cheng XL, Zhao JW
- 2474** Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
Qi JP, Jiang H, Wu T, Zhang Y, Huang W, Li YX, Wang J, Zhang J, Ying ZH
- 2482** Anesthesia management in a pediatric patient with complicatedly difficult airway: A case report
Chen JX, Shi XL, Liang CS, Ma XG, Xu L
- 2489** Intracranial large artery embolism due to carotid thrombosis caused by a neck massager: A case report
Pan J, Wang JW, Cai XF, Lu KF, Wang ZZ, Guo SY
- 2496** Intraductal papillary mucinous neoplasm originating from a jejunal heterotopic pancreas: A case report
Huang JH, Guo W, Liu Z
- 2502** Application of endoscopic retrograde cholangiopancreatography for treatment of obstructive jaundice after hepatoblastoma surgery: A case report
Shu J, Yang H, Yang J, Bian HQ, Wang X
- 2510** Total removal of a large esophageal schwannoma by submucosal tunneling endoscopic resection: A case report and review of literature
Mu YZ, Zhang Q, Zhao J, Liu Y, Kong LW, Ding ZX
- 2521** SMARCA4-deficient undifferentiated thoracic tumor: A case report
Kwon HJ, Jang MH
- 2528** Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report
Zou Q, Shen RL, Guo X, Tang CY
- 2535** Bilateral carpal tunnel syndrome and motor dysfunction caused by gout and type 2 diabetes: A case report
Zhang GF, Rong CM, Li W, Wei BL, Han MT, Han QL
- 2541** Pregnancy complicated by juxtaglomerular cell tumor of the kidney: A case report
Fu X, Deng G, Wang K, Shao C, Xie LP
- 2549** Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports
Zhu Q, Gao BQ, Zhang JF, Shi LP, Zhang GQ
- 2559** Successful treatment of breast metastasis from primary transverse colon cancer: A case report
Jiao X, Xing FZ, Zhai MM, Sun P

- 2567** Different endodontic treatments induced root development of two nonvital immature teeth in the same patient: A case report
Chai R, Yang X, Zhang AS
- 2576** Autoimmune encephalitis after surgery for appendiceal cancer: A case report
Mao YH, Li L, Wen LM, Qin JM, Yang YL, Wang L, Wang FR, Zhao YZ

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Farooq Shahzad, FACS, MBBS, MS, Assistant Professor, Plastic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, United States. fooqs@hotmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

April 16, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Pyroptosis and its role in cancer

Shi-Wei Liu, Wen-Jing Song, Gui-Kai Ma, Hui Wang, Liang Yang

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

P-Reviewer: Arslan M, Turkey;

Portillo R, Czech Republic

Received: December 26, 2022

Peer-review started: December 26, 2022

First decision: February 8, 2023

Revised: February 23, 2023

Accepted: March 14, 2023

Article in press: March 14, 2023

Published online: April 16, 2023



Shi-Wei Liu, Department of Joint Surgery, Dalian Medical University, Dalian 116044, Liaoning Province, China

Wen-Jing Song, Gui-Kai Ma, Hui Wang, Department of Oncology, The First Affiliated Hospital of Weifang Medical University, Weifang 261000, Shandong Province, China

Liang Yang, Department of Joint Surgery, The Second Hospital of Dalian Medical University, Dalian 116023, Liaoning Province, China

Corresponding author: Liang Yang, MD, PhD, Chief Physician, Department of Joint Surgery, The Second Hospital of Dalian Medical University, No. 467 Zhongshan Road, Shahekou District, Dalian 116023, Liaoning Province, China. 18863031115@sohu.com

Abstract

Programmed cell death (PCD) is mediated by specific genes that encode signals. It can balance cell survival and death. Pyroptosis is a type of inflammatory, caspase-dependent PCD mediated by gasdermin proteins, which function in pore formation, cell expansion, and plasma membrane rupture, followed by the release of intracellular contents. Pyroptosis is mediated by caspase-1/3/4/5/11 and is primarily divided into the classical pathway, which is dependent on caspase-1, and the non-classical pathway, which is dependent on caspase-4/5/11. Inflammasomes play a vital role in these processes. The various components of the pyroptosis pathway are related to the occurrence, invasion, and metastasis of tumors. Research on pyroptosis has revealed new options for tumor treatment. This article summarizes the recent research progress on the molecular mechanism of pyroptosis, the relationship between the various components of the pyroptosis pathway and cancer, and the applications and prospects of pyroptosis in anticancer therapy.

Key Words: Pyroptosis; Caspase-1/3/4/5/11; Gasdermin family; Cancer

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Pyroptosis is a type of inflammatory caspase-dependent programmed cell death mediated by gasdermin proteins, which function in pore formation, cell swelling, and cell membrane rupture. This review discusses the classical and non-classical pathways of pyroptosis and the recent research progress on the molecular mechanisms of pyroptosis. We also review the relationship between various pyroptosis pathway components and different cancers, including nucleotide-binding oligomerization domain-like receptor thermal protein domain associated protein 3 inflammasomes, interleukin (IL)-18, IL-1 β , and absent in melanoma 2. The potential applications of this form of cell death as a cancer treatment approach are also explored.

Citation: Liu SW, Song WJ, Ma GK, Wang H, Yang L. Pyroptosis and its role in cancer. *World J Clin Cases* 2023; 11(11): 2386-2395

URL: <https://www.wjgnet.com/2307-8960/full/v11/i11/2386.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i11.2386>

INTRODUCTION

The dynamic balance among cell death, proliferation, and differentiation sustains individual development, homeostasis, and pathological processes in humans. Many disease states are associated with cell death. Programmed cell death (PCD) is regulated by specific cellular mechanisms, and some signaling pathways are activated in these processes[1]. Autophagy, apoptosis, and programmed necrosis are the three main types of PCD[2], and together, they may affect the fate of cancer cells. Apoptosis is a type of PCD that involves cell self-destruction controlled by genes. In apoptosis, the cell membrane remains intact, and inflammation usually does not occur[3]. Necrosis is a passive cell death process caused by pathological stimuli. The permeability of the cell membrane of necrotic cells increases, which causes the cells to swell and finally break down and release their contents. This leads to an inflammatory reaction[3]. Pyroptosis is a form of programmed necrosis, which is PCD induced by gasdermin-mediated.


Pyroptosis was first described in myeloid cells infected by pathogens in 1992[4-6]. It is believed that by clearing intracellular replication niches and improving the defensive responses of the host, pyroptosis plays a vital role in clearing various bacterial and viral infections[7]. The activation of pyroptosis may promote cell death and exert anticancer effects[8]. Pyroptosis has attracted increased attention because it is related to innate immunity and disease. The research status of the relationship between pyroptosis and various cancers is shown in Figure 1, according to publications in PubMed. Emerging evidence has demonstrated the importance of pyroptosis in cancer. Recently, more and more studies have shown that pyroptosis has become a new research topic in cancer, because it may affect the process of cancer. In this review, we outline the molecular mechanism of pyroptosis and highlight its differences from apoptosis. The importance of the various components of the pyroptosis pathway in cancer and its application prospects in antitumor therapy are also discussed.

THE MECHANISM OF PYROPTOSIS

Pyroptosis is also called gasdermin-mediated PCD. The gasdermin family has regulatory functions in normal cell proliferation and differentiation; it includes gasdermin A (GSDMA), gasdermin B (GSDMB), gasdermin C (GSDMC), gasdermin D (GSDMD), gasdermin E (GSDME) (also known as DFNA5, [Deafness, Autosomal Dominant Nonsyndromic Sensorineural 5]), and DFNB59 (Autosomal Recessive Deafness Type 59 Protein)[9-13]. Among them, GSDMD and GSDME have been extensively studied in pyroptosis. These proteins have inherent necrotic activity in their gasdermin-N domain, which is usually masked by their gasdermin-C domain[14-16]. Pyroptosis is activated by various stimuli and inflammatory caspases, which induce the cleavage of proteins in the gasdermin family and release its N-terminal effector and C-terminal inhibitory domains. The necrotic gasdermin-N domain is then transferred to the plasma membrane, forming oligomers[14-19]. These oligomers form transmembrane pores that disrupt the osmotic potential, which results in rapid plasma membrane rupture, causing the cells to release their intracellular contents and pro-inflammatory mediators, such as interleukin (IL)-1 β and IL-18[20].

Of the proteins in the gasdermin family, GSDMA, GSDMB, and GSDMC proteins possess a pore-forming gasdermin-N domain. However, they are not cleaved to form functional pores in response to physiological or pathological stimuli[14,21]. Only GSDMD and GSDME are cleaved by caspases between their gasdermin-N and gasdermin-C domains to form membrane pores[11,14,21-23]. Typically, GSDMD, the downstream effector of inflammasome activation, is cleaved by inflammatory caspases (caspase-1/4/5/11) to induce pyroptosis. However, GSDME is cleaved by an apoptotic caspase

■ Lung cancer and pyroptosis
 ■ Breast cancer and pyroptosis
 ■ Cervical cancer and pyroptosis
 ■ Ovarian cancer and pyroptosis
 ■ Gastric cancer and pyroptosis
 ■ Liver cancer and pyroptosis
 ■ Intestinal cancer and pyroptosis



DOI: 10.12998/wjcc.v11.i11.2386 Copyright ©The Author(s) 2023.


Figure 1 PubMed-searchable publications on pyroptosis and various cancers. Publications were displayed through a search using "pyroptosis and various cancers" on October 7, 2022.

(caspase-3), which causes pyroptotic death[14]. Different molecular patterns are activated depending on the specific signaling pathway and cell type to induce pyroptosis[24]. The role of each component in the gasdermin family is described in [Supplementary Table 1](#).

Pyroptosis belongs to the inflammatory cell death pathway. According to its activation mechanism, pyroptosis can be divided into the classical pathway, which is dependent on caspase-1, and the non-classical pathway, which is dependent on caspase-4, 5, and 11. These pathways are shown in [Figure 2](#). Both pathways are formed by the cleavage of GSDMD, which forms a free N-terminal peptide; this peptide induces cells to form pores and rupture, which causes the release of cytoplasmic components. Both pathways can simultaneously induce the cleavage of IL-1 β and IL-18 precursors to form mature IL-1 β and IL-18. The difference between the two is whether caspase-1 is directly activated. (1) The classical pathway of pyroptosis[21,25]: Inflammasomes are multimolecular complexes that contain pattern-recognition receptors (PRRs). The PRR series usually contains Toll-like receptors, intracellular nucleotide-binding oligomerization domain (NOD)-like receptors, and absent in melanoma-like receptors. PRRs can recognize pathogen-associated and damage-associated molecular patterns, and can sense the presence of risk factors, such as infection and injury. PRRs can also recruit the adaptor protein containing the caspase recruitment domain [apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC)] and activate caspase-1 through the adaptor protein ASC and pro-caspase-1 binding. On the one hand, the activated caspase-1 cleaves GSDMD to form the GSDMD-N and GSDMD-C domains. The GSDMD-N domain combines with phospholipid proteins on the cell membrane to form holes, after which contents are released, and pyroptosis is induced. On the other hand, the activated caspase-1 cleaves IL-1 β and IL-18 precursors to form active IL-1 β and IL-18, which are released outside the cell, causing inflammation; and (2) Non-classical pathways that depend on caspase-4, 5, and 11[21,25]. Taking the inflammatory stimulating factor lipopolysaccharide (LPS) as an example, it directly enters the cytoplasm, although not through the receptor, where it activates other caspases, such as caspase-4, 5, and 11, which cleave GSDMD to induce pyroptosis. A new pathway known to cause pyroptosis is caspase-3/GSDME[11,26]. Caspase-3 can be activated by death receptors and mitochondrial pathways. Mature caspase-3 cleaves GSDME to produce GSDME N-fragments. It participates in pore formation in the plasma membrane, resulting in cell swelling and pyroptosis.

THE RELATIONSHIP BETWEEN VARIOUS COMPONENTS IN THE PYROPTOSIS PATHWAY AND CANCER

Pyroptosis is an important natural immune response of the body. It plays a vital role in antagonizing infection and endogenous danger signals. Pyroptosis is widely involved in the occurrence and development of infectious, nervous system-related, and atherosclerotic diseases. In-depth research on pyroptosis has implicated its role in the occurrence, development, and outcome of related diseases and has provided new ideas for clinical prevention and treatment. In recent years, research interest in pyroptosis has increased significantly as it has successfully attracted the attention of scientists and has become a popular research topic. For tumors, pyroptosis is a double-edged sword. On the one hand, as



DOI: 10.12998/wjcc.v11.i11.2386 Copyright ©The Author(s) 2023.

Figure 2 Molecular mechanism of pyroptosis. Pyroptosis belongs to the inflammatory death pathway. It can be divided into the classical pathway, which is dependent on caspase-1, and the non-classical pathway, which is dependent on caspase-4, 5, and 11. A: The classical pyroptosis pathway: Upon sensing pathogen-associated molecular patterns, damage-associated molecular patterns, or other cytosolic disturbances, caspase-1 is activated via the recruitment of ASC. Caspase-1 successively promotes the maturation of pro-IL-18/1 β and cleaves GSDMD to form GSDMD-N and GSDMD-C domains. The GSDMD-N domain interacts with phospholipid proteins on the cell membrane to form holes, leading to the secretion of IL-1 β /18 and water influx and causing cell swelling and osmotic lysis; B: The non-classical pathway that depends on caspase-4, 5, and 11: When lipopolysaccharide derived from bacteria recognizes and activates caspase-11/4/5, it can also cause pyroptosis by cleavage of GSDMD; C: A new pathway to cause pyroptosis is caspase-3/GSDME. Caspase-3 can be activated by the death receptor and mitochondrial pathway. Mature caspase-3 cleaves GSDME to produce GSDME N-fragments and participates in pore formation in the plasma membrane, which results in cell swelling and pyroptosis. ASC: Apoptosis-associated speck-like protein containing a caspase recruitment domain; IL: Interleukin; GSDMD: Gasdermin D; GSDME: Gasdermin E; NLRP1: NOD-like receptor protein 1; NLRP3: NOD-like receptor protein 3; AIM2: Absent in melanoma 2; NLRC4: NLR family CARD domain-containing protein 4; LPS: Lipopolysaccharide.

an innate immune mechanism, pyroptosis can inhibit the occurrence and development of tumors. On the other hand, as a mechanism of pro-inflammatory cell death, pyroptosis provides a suitable microenvironment for tumor growth. The key components of the pyroptosis pathway, inflammasomes, gasdermin proteins, and pro-inflammatory cytokines, are all related to tumor occurrence, invasion, and metastasis[27].

GSDMD AND CANCER

Many molecules that participate in the pyroptosis process are closely related to the occurrence and development of lung cancer. Studies have confirmed that the expression level of GSDMD in non-small cell lung cancer is significantly higher than in surrounding lung tissues. Moreover, the GSDMD expression is related to the tumor size, tumor-node-metastasis stage, and high aggressive characteristics[28]. In addition, GSDMD is considered to be an independent prognostic marker of lung adenocarcinoma[28]. Studies have found that GSDMD in gastric cancer was downregulated and led to the occurrence and spread of this cancer type[29]. The low level of GSDMD in gastric cancer cells may be associated with the acceleration of the cell cycle S/G2 transition; GSDMD also inhibits the signal transducer and activator of transcription 3, extracellular signal-regulated kinase (ERK), and

phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) in gastric cancer. These data indicate the tumor-suppressive effect of GSDMD in gastric cancer. However, whether GSDMD plays a tumor-suppressive or cancer-promoting role in breast and colorectal cancers and other cancers is unknown. Therefore, this will be the focus of future research.

GSDME AND CANCER

In lung cancer, the deletion of the *DFNA5/GSDME* gene promotes drug resistance, whereas the overexpression of *DFNA5/GSDME* can result in increased drug sensitivity[30]. Both cisplatin and paclitaxel can induce pyroptosis through caspase-3/GSDME activation. However, in A549 Lung cancer cells, cisplatin is more effective than paclitaxel in triggering pyroptosis[31]. According to several studies, the expression of *DFNA5/GSDME* in hepatocellular carcinoma (HCC) cells was significantly reduced compared to that in normal cells. Furthermore, the upregulation of the *DFNA5/GSDME* expression inhibited cell proliferation, which suggests that *DFNA5/GSDME* may be an anticancer gene[10,32]. Studies have found that GSDME knockout can significantly inhibit breast cancer (BC) cell pyroptosis and reduce the sensitivity of cancer cells to paclitaxel. In addition, GSDME methylation can increase the risk of BC lymph node metastasis, which suggests that GSDME exerts anticancer effects. Recent studies have suggested that chemotherapeutics can convert caspase-3-dependent apoptosis into pyroptosis *via* *DFNA5/GSDME*, which may be downregulated because of promoter methylation[33]. Treatment with decitabine can induce *DFNA5/GSDME* up-regulation in cancer cells, which causes pyroptosis and increases the sensitivity of these cells to chemotherapeutics[11,34].

NOD-LIKE RECEPTOR PROTEIN 3 AND CANCER

Studies have reported that stimulating the formation of NOD-like receptor protein 3 (NLRP3) inflammasomes in A549 lung cancer cells with LPS and adenosine triphosphate can activate AKT, ERK1/2, and cyclic adenosine monophosphate response element binding protein. Moreover, it can upregulate the transcription factor Snail and downregulate E-cadherin, which confirms that the NLRP3 inflammasome can promote lung cancer cell proliferation and migration[35]. In BC, the production of NLRP3 inflammasomes and IL-1 β promote the infiltration of bone marrow cells, such as tumor-associated macrophages and myeloid-derived suppressor cells, which provide an inflammatory microenvironment that promotes BC progression[36]. Furthermore, NLRP3 inflammasomes in fibroblasts are associated with progression and metastasis[37]. The NLRP3 inflammasome appears to be an effector that promotes lymphatic system metastasis and BC development[38]. Various components involved in pyroptosis are closely related to digestive system tumors. Studies have found that the NLRP3 expression in HCC is significantly downregulated or even absent and that its expression is negatively correlated with the clinical stage and pathological grade. This suggests that the NLRP3 inflammasome participates in developing HCC[39]. Furthermore, the NLRP3 inflammasome participates in the innate immune response to cervical cancer, and its expression is widely present in tumor cells[40,41]. The NLRP3 inflammasome activation can be achieved through lysosomal rupture, hemi-ion channels, and reactive oxygen species (ROS). In cervical cancer, the NLRP3 inflammasome is mainly activated by ROS to induce pyroptosis. In most of the cited reports, evidence on the role of NLRP3 in tumors is still in the preliminary stage, and further confirmation is needed to determine the potential therapeutic role of NLRP3 inflammasomes in human malignancies.

IL-18 AND CANCER

IL-18 plays an immunomodulatory role in the occurrence of esophageal squamous cell carcinoma (ESCC)[42,43]. IL-18 can induce CD8⁺ T cells and natural killer cells to produce interferon- γ , improve anticancer immunity, and inhibit cancer cell proliferation and metastasis[42]. Exogenous IL-18 is expected to be a new approach for treating ESCC. In one study, the vascular endothelial growth factor stimulated the production, processing, and secretion of IL-18 in gastric cancer cells. IL-18 promotes cell migration through actin polymerization and tensin down-regulation. Therefore, IL-18 may amplify the angiogenesis, migration, and progression of gastric cancer cells[44,45]. In addition to the angiogenic and invasive properties of IL-18, this cytokine can also induce the expression of protease inhibitor 9 and granzyme B inhibitor in gastric cancer cells, which reduces their sensitivity to lymphocyte-mediated cytotoxicity[46]. Recent data indicate that the NLRP3 inflammatory body inhibitor thymoquinone and resveratrol inhibit the metastases of murine melanoma cells by inhibiting the IL-18-mediated vascular cell adhesion molecule 1 expression and IL-18 secretion[47,48]. Different studies have reported the association between polymorphisms in the IL-18 gene promoter (-137 G>C and -607 C>A) and the development of different human cancers. A meta-analysis showed that the -137 G>C polymorphism is

associated with an increased risk of nasopharyngeal carcinoma (NPC) in Asian populations but not in Caucasian populations[49]. Another meta-analysis showed that the -607 C>A polymorphism is connected with an increase in the overall cancer risk, especially for esophageal cancer and NPC, in Asian populations[50]. Recently, the discovery of IL-18-binding protein (IL-18BP) as a physiological inhibitor of IL-18 has suggested that this cytokine may be an attractive target. Its advantages and disadvantages in treating various diseases are currently being investigated[51,52]. In some types of tumors, the tumor-promoting effect of IL-18 is dominant, and IL-18BP may be beneficial. Therefore, any potential IL-18 treatment should be considered with caution.

IL-1B AND CANCER

IL-1 β can promote epithelial-mesenchymal transition (EMT) in ESCC, colorectal carcinoma (CRC), and HCC, and it can promote the migration and invasiveness of cancer cells[53-56]. Multiple studies have found that IL-1 β is a crucial cytokine related to BC. IL-1 β can induce the EMT process in BC, increase tumor malignancy, and increase the resistance of BC to cisplatin by upregulating resistance-related genes. IL-1 β can also promote the expression of the oncogene baculoviral inhibitor of apoptosis repeat-containing 3 to decrease the resistance of BC to doxorubicin[56]. Moreover, other studies have reported that IL-1 β can induce tamoxifen resistance in BC by downregulating estrogen receptor- α [57]. In response to the cancer-promoting effect of IL-1 β , Tulotta *et al*[53] used anakinra and kanazumab to block the IL-1 β signaling pathway. They found that the body's anticancer immunity was enhanced, the number of cancer cells entering the circulation was decreased, and the metastasis of BC was suppressed. In the future, it is hoped that antitumor drugs that target IL-1 β will become novel cancer therapies.

AIM2 (ABSENT IN MELANOMA 2) AND CANCER

AIM2 is a cytoplasmic sensor that recognizes double-stranded DNA (dsDNA) released during cellular perturbation and pathogenic assault[58]. Upon binding to dsDNA, AIM2 assembles a multiprotein complex termed the inflammasome, which drives IL-1 β and IL-18 secretion and pyroptosis[59]. Several studies observed a decreased AIM2 expression in HCC tissues but not in normal tissues. The AIM2 expression was negatively correlated with tumor progression[60,61]. Additionally, AIM2 deficiency enhanced EMT and fibronectin-1 expression, which may be related to HCC metastasis[60]. In human papillomavirus-infected cervical cancer cells, AIM2 can exert a tumor-inhibitory effect by stimulating pyroptosis[62]. The AIM2 gene contains a microsatellite instability site, leading to frequent gene mutations in CRC and small intestine cancer[63,64]. Two independent studies have shown that AIM2 can inhibit CRC development[65,66]; AIM2 inhibits the proliferation of colonic stem cells and facilitates cell death by inhibiting the PI3K/AKT signaling pathway[65,66]. In addition, studies have shown that AIM2 inhibits the proliferation of colon cancer cells in the G2/M phase by inducing cell cycle arrest[67]. Furthermore, the release of IL-18 mediated by the AIM2 inflammasome triggers the up-regulation of IL-22 binding protein and antimicrobial peptides that regulate intestinal homeostasis[68]. A high AIM2 expression is associated with the increased survival rate of patients with Epstein-Barr virus-associated NPC. The function of AIM2 in NPC may involve IL-1 β and the recruitment of immunostimulatory neutrophils into tumor masses, which can mediate antitumor activity[69]. Depending on cancer, AIM2 plays different roles; for example, AIM2 functions as a tumor suppressor in CRC and HCC but as a tumor promoter in skin carcinoma[70]. The AIM2 expression is moderate in skin squamous cell carcinoma, whereas its expression is low or absent in normal skin. The knockdown of AIM2 also leads to the reduced invasiveness of skin squamous cell carcinoma cells. It can inhibit the growth and vascularization of skin squamous cell carcinoma *in vivo*[70]. Further research on AIM2 will help us better understand the role of AIM2 in cancer and to develop new antitumor drugs.

CONCLUSION

Pyroptosis is a type of inflammatory PCD characterized by cell swelling and lysis that is mediated by various inflammasomes, which can discern danger signals and activate the secretion of pro-inflammatory cytokines (such as IL-18 and IL-1 β). Pyroptosis can regulate cell proliferation, infiltration, migration, chemotherapy resistance, and other malignant phenotypes through various cell signaling pathways, thereby affecting tumor progression. The various components of the pyroptosis pathway are involved in almost all aspects of tumor development. They play either a tumor-suppressive or a pro-tumorigenic role. Therefore, research on the characteristics and mechanisms of pyroptosis and its relationship with cancer can provide novel ideas and effective drug targets for disease prevention and treatment.

FOOTNOTES

Author contributions: Song WJ and Yang L contributed to conceptualization; Ma GK and Wang H contributed to data collection and analysis; Liu SW, Song WJ, and Ma GK contributed to manuscript writing; Yang L contributed to final approval of manuscript; All authors contributed to the article and approved the submitted version.

Conflict-of-interest statement: All the authors report no conflict of interest in this work.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Wen-Jing Song 0000-0003-2583-4362; Liang Yang 0000-0002-9099-1738.

S-Editor: Liu JH

L-Editor: A

P-Editor: Liu JH

REFERENCES

- Andón FT, Fadeel B. Programmed cell death: molecular mechanisms and implications for safety assessment of nanomaterials. *Acc Chem Res* 2013; **46**: 733-742 [PMID: 22720979 DOI: 10.1021/ar300020b]
- Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. *Cell Prolif* 2012; **45**: 487-498 [PMID: 23030059 DOI: 10.1111/j.1365-2184.2012.00845.x]
- Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. *Infect Immun* 2005; **73**: 1907-1916 [PMID: 15784530 DOI: 10.1128/iai.73.4.1907-1916.2005]
- Wallach D, Kang TB, Dillon CP, Green DR. Programmed necrosis in inflammation: Toward identification of the effector molecules. *Science* 2016; **352**: aaf2154 [PMID: 27034377 DOI: 10.1126/science.aaf2154]
- Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. *Trends Biochem Sci* 2017; **42**: 245-254 [PMID: 27932073 DOI: 10.1016/j.tibs.2016.10.004]
- Zychlinsky A, Prevost MC, Sansonetti PJ. Shigella flexneri induces apoptosis in infected macrophages. *Nature* 1992; **358**: 167-169 [PMID: 1614548 DOI: 10.1038/358167a0]
- Jorgensen I, Miao EA. Pyroptotic cell death defends against intracellular pathogens. *Immunol Rev* 2015; **265**: 130-142 [PMID: 25879289 DOI: 10.1111/imr.12287]
- Li L, Li Y, Bai Y. Role of GSDMB in Pyroptosis and Cancer. *Cancer Manag Res* 2020; **12**: 3033-3043 [PMID: 32431546 DOI: 10.2147/CMAR.S246948]
- Burgener SS, Leborgne NGF, Snipas SJ, Salvesen GS, Bird PI, Benarafa C. Cathepsin G Inhibition by Serpinb1 and Serpinb6 Prevents Programmed Necrosis in Neutrophils and Monocytes and Reduces GSDMD-Driven Inflammation. *Cell Rep* 2019; **27**: 3646-3656.e5 [PMID: 31216481 DOI: 10.1016/j.celrep.2019.05.065]
- Wang CJ, Tang L, Shen DW, Wang C, Yuan QY, Gao W, Wang YK, Xu RH, Zhang H. The expression and regulation of DFNA5 in human hepatocellular carcinoma DFNA5 in hepatocellular carcinoma. *Mol Biol Rep* 2013; **40**: 6525-6531 [PMID: 24154762 DOI: 10.1007/s11033-013-2581-8]
- Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *Nature* 2017; **547**: 99-103 [PMID: 28459430 DOI: 10.1038/nature22393]
- Tamura M, Tanaka S, Fujii T, Aoki A, Komiyama H, Ezawa K, Sumiyama K, Sagai T, Shiroishi T. Members of a novel gene family, Gsdm, are expressed exclusively in the epithelium of the skin and gastrointestinal tract in a highly tissue-specific manner. *Genomics* 2007; **89**: 618-629 [PMID: 17350798 DOI: 10.1016/j.ygeno.2007.01.003]
- Wei Q, Zhu R, Zhu J, Zhao R, Li M. E2-Induced Activation of the NLRP3 Inflammasome Triggers Pyroptosis and Inhibits Autophagy in HCC Cells. *Oncol Res* 2019; **27**: 827-834 [PMID: 30940293 DOI: 10.3727/096504018X15462920753012]
- Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, Sun H, Wang DC, Shao F. Pore-forming activity and structural autoinhibition of the gasdermin family. *Nature* 2016; **535**: 111-116 [PMID: 27281216 DOI: 10.1038/nature18590]
- Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. *Nat Commun* 2017; **8**: 14128 [PMID: 28045099 DOI: 10.1038/ncomms14128]
- Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, Lieberman J. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. *Nature* 2016; **535**: 153-158 [PMID: 27383986 DOI: 10.1038/nature18629]
- Aglietti RA, Estevez A, Gupta A, Ramirez MG, Liu PS, Kayagaki N, Ciferri C, Dixit VM, Dueber EC. GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. *Proc Natl Acad Sci USA* 2016; **113**: 7858-7863 [PMID: 27339137 DOI: 10.1073/pnas.1607769113]
- Russo HM, Rathkey J, Boyd-Tressler A, Katsnelson MA, Abbott DW, Dubyak GR. Active Caspase-1 Induces Plasma Membrane Pores That Precede Pyroptotic Lysis and Are Blocked by Lanthanides. *J Immunol* 2016; **197**: 1353-1367

- [PMID: 27385778 DOI: 10.4049/jimmunol.1600699]
- 19 **Sborgi L**, Rühl S, Mulvihill E, Pipercevic J, Heilig R, Stahlberg H, Farady CJ, Müller DJ, Broz P, Hiller S. GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death. *EMBO J* 2016; **35**: 1766-1778 [PMID: 27418190 DOI: 10.15252/embj.201694696]
 - 20 **Pizato N**, Luzete BC, Kiffer LFMV, Corrêa LH, de Oliveira Santos I, Assumpção JAF, Ito MK, Magalhães KG. Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells. *Sci Rep* 2018; **8**: 1952 [PMID: 29386662 DOI: 10.1038/s41598-018-20422-0]
 - 21 **Shi J**, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature* 2015; **526**: 660-665 [PMID: 26375003 DOI: 10.1038/nature15514]
 - 22 **He WT**, Wan H, Hu L, Chen P, Wang X, Huang Z, Yang ZH, Zhong CQ, Han J. Gasdermin D is an executor of pyroptosis and required for interleukin-1 β secretion. *Cell Res* 2015; **25**: 1285-1298 [PMID: 26611636 DOI: 10.1038/cr.2015.139]
 - 23 **Kayagaki N**, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT, Liu PS, Lill JR, Li H, Wu J, Kummerfeld S, Zhang J, Lee WP, Snipas SJ, Salvesen GS, Morris LX, Fitzgerald L, Zhang Y, Bertram EM, Goodnow CC, Dixit VM. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature* 2015; **526**: 666-671 [PMID: 26375259 DOI: 10.1038/nature15541]
 - 24 **Wimmer K**, Sachet M, Oehler R. Circulating biomarkers of cell death. *Clin Chim Acta* 2020; **500**: 87-97 [PMID: 31655053 DOI: 10.1016/j.cca.2019.10.003]
 - 25 **Ding J**, Wang K, Liu W, She Y, Sun Q, Shi J, Sun H, Wang DC, Shao F. Erratum: Pore-forming activity and structural autoinhibition of the gasdermin family. *Nature* 2016; **540**: 150 [PMID: 27706141 DOI: 10.1038/nature20106]
 - 26 **Zhang Z**, Zhang H, Li D, Zhou X, Qin Q, Zhang Q. Caspase-3-mediated GSDME induced Pyroptosis in breast cancer cells through the ROS/JNK signalling pathway. *J Cell Mol Med* 2021; **25**: 8159-8168 [PMID: 34369076 DOI: 10.1111/jcmm.16574]
 - 27 **Kolb R**, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. *Protein Cell* 2014; **5**: 12-20 [PMID: 24474192 DOI: 10.1007/s13238-013-0001-4]
 - 28 **Gao J**, Qiu X, Xi G, Liu H, Zhang F, Lv T, Song Y. Downregulation of GSDMD attenuates tumor proliferation *via* the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in nonsmall cell lung cancer. *Oncol Rep* 2018; **40**: 1971-1984 [PMID: 30106450 DOI: 10.3892/or.2018.6634]
 - 29 **Wang WJ**, Chen D, Jiang MZ, Xu B, Li XW, Chu Y, Zhang YJ, Mao R, Liang J, Fan DM. Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins. *J Dig Dis* 2018; **19**: 74-83 [PMID: 29314754 DOI: 10.1111/1751-2980.12576]
 - 30 **Lu H**, Zhang S, Wu J, Chen M, Cai MC, Fu Y, Li W, Wang J, Zhao X, Yu Z, Ma P, Zhuang G. Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death. *Clin Cancer Res* 2018; **24**: 6066-6077 [PMID: 30061362 DOI: 10.1158/1078-0432.CCR-18-1478]
 - 31 **Zhang CC**, Li CG, Wang YF, Xu LH, He XH, Zeng QZ, Zeng CY, Mai FY, Hu B, Ouyang DY. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells *via* caspase-3/GSDME activation. *Apoptosis* 2019; **24**: 312-325 [PMID: 30710195 DOI: 10.1007/s10495-019-01515-1]
 - 32 **Sharma D**, Malik A, Guy CS, Karki R, Vogel P, Kanneganti TD. P2Y₁ Inflammasome Regulates Tight Junction Integrity to Restrict Colitis and Tumorigenesis. *Gastroenterology* 2018; **154**: 948-964.e8 [PMID: 29203393 DOI: 10.1053/j.gastro.2017.11.276]
 - 33 **Wang Y**, Yin B, Li D, Wang G, Han X, Sun X. GSDME mediates caspase-3-dependent pyroptosis in gastric cancer. *Biochem Biophys Res Commun* 2018; **495**: 1418-1425 [PMID: 29183726 DOI: 10.1016/j.bbrc.2017.11.156]
 - 34 **Feng S**, Fox D, Man SM. Mechanisms of Gasdermin Family Members in Inflammasome Signaling and Cell Death. *J Mol Biol* 2018; **430**: 3068-3080 [PMID: 29990470 DOI: 10.1016/j.jmb.2018.07.002]
 - 35 **Wang Y**, Kong H, Zeng X, Liu W, Wang Z, Yan X, Wang H, Xie W. Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. *Oncol Rep* 2016; **35**: 2053-2064 [PMID: 26782741 DOI: 10.3892/or.2016.4569]
 - 36 **Guo B**, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome/IL-1 pathways for cancer immunotherapy. *Sci Rep* 2016; **6**: 36107 [PMID: 27786298 DOI: 10.1038/srep36107]
 - 37 **Ershaid N**, Sharon Y, Doron H, Raz Y, Shani O, Cohen N, Monteran L, Leider-Trejo L, Ben-Shmuel A, Yassin M, Gerlic M, Ben-Baruch A, Pasmanik-Chor M, Apte R, Erez N. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis. *Nat Commun* 2019; **10**: 4375 [PMID: 31558756 DOI: 10.1038/s41467-019-12370-8]
 - 38 **Weichand B**, Popp R, Dziubla S, Mora J, Strack E, Elwakeel E, Frank AC, Scholich K, Pierre S, Syed SN, Olesch C, Ringleb J, Ören B, Döring C, Savai R, Jung M, von Knethen A, Levkau B, Fleming I, Weigert A, Brüne B. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis *via* NLRP3/IL-1 β . *J Exp Med* 2017; **214**: 2695-2713 [PMID: 28739604 DOI: 10.1084/jem.20160392]
 - 39 **Wei Q**, Mu K, Li T, Zhang Y, Yang Z, Jia X, Zhao W, Huai W, Guo P, Han L. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. *Lab Invest* 2014; **94**: 52-62 [PMID: 24166187 DOI: 10.1038/labinvest.2013.126]
 - 40 **Zhang H**, Li L, Liu L. Fc γ RI (CD64) contributes to the severity of immune inflammation through regulating NF- κ B/NLRP3 inflammasome pathway. *Life Sci* 2018; **207**: 296-303 [PMID: 29920250 DOI: 10.1016/j.lfs.2018.06.015]
 - 41 **Hoseini Z**, Sepahvand F, Rashidi B, Sahebkar A, Masoudifar A, Mirzaei H. NLRP3 inflammasome: Its regulation and involvement in atherosclerosis. *J Cell Physiol* 2018; **233**: 2116-2132 [PMID: 28345767 DOI: 10.1002/jcp.25930]
 - 42 **Li J**, Qiu G, Fang B, Dai X, Cai J. Deficiency of IL-18 Aggravates Esophageal Carcinoma Through Inhibiting IFN- γ Production by CD8(+)T Cells and NK Cells. *Inflammation* 2018; **41**: 667-676 [PMID: 29264744 DOI: 10.1007/s10753-017-0721-3]
 - 43 **Wei YS**, Lan Y, Liu YG, Tang H, Tang RG, Wang JC. Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. *Acta Oncol* 2007; **46**: 1090-1096 [PMID: 17851835 DOI: 10.1080/02801830600571111]

- 10.1080/02841860701373595]
- 44 **Kim KE**, Song H, Kim TS, Yoon D, Kim CW, Bang SI, Hur DY, Park H, Cho DH. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. *Oncogene* 2007; **26**: 1468-1476 [PMID: 17001321 DOI: 10.1038/sj.onc.1209926]
 - 45 **Kim KE**, Song H, Hahm C, Yoon SY, Park S, Lee HR, Hur DY, Kim T, Kim CH, Bang SI, Bang JW, Park H, Cho DH. Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. *J Immunol* 2009; **182**: 3548-3555 [PMID: 19265133 DOI: 10.4049/jimmunol.0801695]
 - 46 **Majima T**, Ichikura T, Chochi K, Kawabata T, Tsujimoto H, Sugawara H, Kuranaga N, Takayama E, Kinoshita M, Hiraide H, Seki S, Mochizuki H. Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. *Int J Cancer* 2006; **118**: 388-395 [PMID: 16049975 DOI: 10.1002/ijc.21334]
 - 47 **Ahmad I**, Muneer KM, Tamimi IA, Chang ME, Ata MO, Yusuf N. Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome. *Toxicol Appl Pharmacol* 2013; **270**: 70-76 [PMID: 23583630 DOI: 10.1016/j.taap.2013.03.027]
 - 48 **Salado C**, Olaso E, Gallot N, Valcarcel M, Egilegor E, Mendoza L, Vidal-Vanaclocha F. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. *J Transl Med* 2011; **9**: 59 [PMID: 21569399 DOI: 10.1186/1479-5876-9-59]
 - 49 **Yang X**, Qiu MT, Hu JW, Jiang F, Li M, Wang J, Zhang Q, Yin R, Xu L. Association of interleukin-18 gene promoter -607 C>A and -137G>C polymorphisms with cancer risk: a meta-analysis of 26 studies. *PLoS One* 2013; **8**: e73671 [PMID: 24066061 DOI: 10.1371/journal.pone.0073671]
 - 50 **Wang M**, Zhu XY, Wang L, Lin Y. The -607C/A polymorphisms in interleukin-18 gene promoter contributes to cancer risk: evidence from a meta-analysis of 22 case-control studies. *PLoS One* 2013; **8**: e76915 [PMID: 24130810 DOI: 10.1371/journal.pone.0076915]
 - 51 **Esmailbeig M**, Ghaderi A. Interleukin-18: a regulator of cancer and autoimmune diseases. *Eur Cytokine Netw* 2017; **28**: 127-140 [PMID: 29478963 DOI: 10.1684/ecn.2018.0401]
 - 52 **Fabbi M**, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. *J Leukoc Biol* 2015; **97**: 665-675 [PMID: 25548255 DOI: 10.1189/jlb.5RU0714-360RR]
 - 53 **Tulotta C**, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X, Bradbury SMJ, Hambley L, Cookson V, Allocca G, Kruithof de Julio M, Coleman RE, Brown JE, Holen I, Ottewill PD. Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. *Clin Cancer Res* 2019; **25**: 2769-2782 [PMID: 30670488 DOI: 10.1158/1078-0432.CCR-18-2202]
 - 54 **Yu Q**, Zhang M, Ying Q, Xie X, Yue S, Tong B, Wei Q, Bai Z, Ma L. Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment. *Cell Death Dis* 2019; **10**: 218 [PMID: 30833546 DOI: 10.1038/s41419-019-1447-y]
 - 55 **Chen L**, Weng B, Li H, Wang H, Li Q, Wei X, Deng H, Wang S, Jiang C, Lin R, Wu J. A thiopyran derivative with low murine toxicity with therapeutic potential on lung cancer acting through a NF- κ B mediated apoptosis-to-pyroptosis switch. *Apoptosis* 2019; **24**: 74-82 [PMID: 30519834 DOI: 10.1007/s10495-018-1499-y]
 - 56 **Storr SJ**, Safuan S, Ahmad N, El-Refaei M, Jackson AM, Martin SG. Macrophage-derived interleukin-1 β promotes human breast cancer cell migration and lymphatic adhesion in vitro. *Cancer Immunol Immunother* 2017; **66**: 1287-1294 [PMID: 28551814 DOI: 10.1007/s00262-017-2020-0]
 - 57 **Jiménez-Garduño AM**, Mendoza-Rodríguez MG, Urrutia-Cabrera D, Domínguez-Robles MC, Pérez-Yépez EA, Ayala-Sumano JT, Meza I. IL-1 β induced methylation of the estrogen receptor ER α gene correlates with EMT and chemoresistance in breast cancer cells. *Biochem Biophys Res Commun* 2017; **490**: 780-785 [PMID: 28645612 DOI: 10.1016/j.bbrc.2017.06.117]
 - 58 **Sharma BR**, Karki R, Kanneganti TD. Role of AIM2 inflammasome in inflammatory diseases, cancer and infection. *Eur J Immunol* 2019; **49**: 1998-2011 [PMID: 31372985 DOI: 10.1002/eji.201848070]
 - 59 **Man SM**, Karki R, Kanneganti TD. AIM2 inflammasome in infection, cancer, and autoimmunity: Role in DNA sensing, inflammation, and innate immunity. *Eur J Immunol* 2016; **46**: 269-280 [PMID: 26626159 DOI: 10.1002/eji.201545839]
 - 60 **Chen SL**, Liu LL, Lu SX, Luo RZ, Wang CH, Wang H, Cai SH, Yang X, Xie D, Zhang CZ, Yun JP. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. *Mol Oncol* 2017; **11**: 1225-1240 [PMID: 28580773 DOI: 10.1002/1878-0261.12090]
 - 61 **Ma X**, Guo P, Qiu Y, Mu K, Zhu L, Zhao W, Li T, Han L. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway. *Oncotarget* 2016; **7**: 36185-36197 [PMID: 27167192 DOI: 10.18632/oncotarget.9154]
 - 62 **So D**, Shin HW, Kim J, Lee M, Myeong J, Chun YS, Park JW. Cervical cancer is addicted to SIRT1 disarming the AIM2 antiviral defense. *Oncogene* 2018; **37**: 5191-5204 [PMID: 29844574 DOI: 10.1038/s41388-018-0339-4]
 - 63 **Mori Y**, Yin J, Rashid A, Leggett BA, Young J, Simms L, Kuehl PM, Langenberg P, Meltzer SJ, Stine OC. Instability typing: comprehensive identification of frameshift mutations caused by coding region microsatellite instability. *Cancer Res* 2001; **61**: 6046-6049 [PMID: 11507051]
 - 64 **Schulmann K**, Brasch FE, Kunstmann E, Engel C, Pagenstecher C, Vogelsang H, Krüger S, Vogel T, Knaebel HP, Rüschoff J, Hahn SA, Knebel-Doeberitz MV, Moeslein G, Meltzer SJ, Schackert HK, Tympner C, Mangold E, Schmiegel W; German HNPCC Consortium. HNPCC-associated small bowel cancer: clinical and molecular characteristics. *Gastroenterology* 2005; **128**: 590-599 [PMID: 15765394 DOI: 10.1053/j.gastro.2004.12.051]
 - 65 **Wilson JE**, Petrucelli AS, Chen L, Koblansky AA, Truax AD, Oyama Y, Rogers AB, Brickey WJ, Wang Y, Schneider M, Mühlbauer M, Chou WC, Barker BR, Jobin C, Allbritton NL, Ramsden DA, Davis BK, Ting JP. Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt. *Nat Med* 2015; **21**: 906-913 [PMID: 26107252 DOI: 10.1038/nm.3908]
 - 66 **Man SM**, Zhu Q, Zhu L, Liu Z, Karki R, Malik A, Sharma D, Li L, Malireddi RK, Gurung P, Neale G, Olsen SR, Carter RA, McGoldrick DJ, Wu G, Finkelstein D, Vogel P, Gilbertson RJ, Kanneganti TD. Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer. *Cell* 2015; **162**: 45-58 [PMID: 26095253 DOI: 10.1016/j.cell.2015.06.001]

- 67 **Patsos G**, Germann A, Gebert J, Dihlmann S. Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. *Int J Cancer* 2010; **126**: 1838-1849 [PMID: [19795419](#) DOI: [10.1002/ijc.24905](#)]
- 68 **Ratsimandresy RA**, Indramohan M, Dorfleutner A, Stehlik C. The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. *Cell Mol Immunol* 2017; **14**: 127-142 [PMID: [27524110](#) DOI: [10.1038/cmi.2016.35](#)]
- 69 **Chen LC**, Wang LJ, Tsang NM, Ojcius DM, Chen CC, Ouyang CN, Hsueh C, Liang Y, Chang KP, Chang YS. Tumour inflammasome-derived IL-1 β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. *EMBO Mol Med* 2012; **4**: 1276-1293 [PMID: [23065753](#) DOI: [10.1002/emmm.201201569](#)]
- 70 **Farshchian M**, Nissinen L, Siljamäki E, Riihilä P, Piipponen M, Kivisaari A, Kallajoki M, Grénman R, Peltonen J, Peltonen S, Quint KD, Bavinck JNB, Kähäri VM. Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma. *Oncotarget* 2017; **8**: 45825-45836 [PMID: [28526809](#) DOI: [10.18632/oncotarget.17573](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

